Drugs / MTP-101P
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06692179 | Feb 2025 → Jun 2026 | Clostridium difficile colitis | University of Minnesota | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06503978 | Aug 2024 → Jul 2025 overdue | autism spectrum disorder, constipation disorder, diarrheal disease | Gut-Brain-Axis Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06321796 | Feb 2024 → Feb 2025 | Pitt-Hopkins syndrome | Gut-Brain-Axis Therapeutics Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTP-101P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06692179 ↗ |
| Modality | Other / unclassified | “MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors.” NCT06321796 ↗ |
| Route | Oral | “orally administered” NCT06692179 ↗ |